Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Study Identifies Growth Factor Receptors That May Prompt the Spread of Lung Cancer

Published: Thursday, April 10, 2014
Last Updated: Thursday, April 10, 2014
Bookmark and Share
Preventing lung cancers from metastasizing to other parts of the body could provide benefit for patients against the leading cause of cancer death.

Two cell surface receptors might be responsible for the most common form of lung cancer spreading to other parts of the body, according to a study led by the Translational Genomics Research Institute (TGen).

The hepatocyte growth factor receptor (HGFR/MET) and fibroblast growth factor-inducible 14 (FN14) are proteins associated with the potential spread of non-small cell lung cancer (NSCLC), according to the TGen study published online April 8 by the scientific journal Clinical & Experimental Metastasis.

NSCLC represents more than 85 percent of all lung cancers, which this year will kill an estimated 159,000 Americans, making it by far the leading cause of cancer-related death. It has a 5-year survival rate less than 10 percent.

The invasive and metastatic nature of NSCLC contributes to this high mortality rate, and so finding the cause of this potential to spread is key to helping patients survive.

Therapies targeting MET and FN14 are in clinical development, which could lead to treatments that could help halt or slow the spread of this lung cancer.

"As the metastatic phenotype is a major cause of lung cancer mortality, understanding and potentially targeting these pathways may reduce the high mortality rate in advanced lung cancer," said Dr. Timothy Whitsett, an Assistant Professor in TGen's Cancer and Cell Biology Division, and the study's lead author.

Significantly, the TGen study found that MET and FN14 were elevated in metastatic tumors compared to primary lung tumors and suppression of MET activation or FN14 expression reduced tumor cell invasion.    

"The elevation of these receptors in metastatic disease opens the possibility for therapeutic intervention," said Dr. Nhan Tran, an Associate Professor in TGen's Cancer and Cell Biology Division, and the study's senior author.

Dr. Glen Weiss, Co-Unit Head of TGen's Lung Cancer Research Laboratory and Director of Clinical Research at Cancer Treatment Centers of America at Western Regional Medical Center, said, "This study identifies some targets that already have drugs in clinical trials, and helps put them into context for what might be a rational drug development approach for the treatment of this deadly cancer."

Other institutes that assisted with this study are: the University of Arizona; St. Joseph's Hospital and Medical Center; and Humboldt Medical Specialists.

The study, FN14 expression correlates with MET in NSCLC and promotes MET-driven cell invasion, was funded by the National Institutes of Health, and grants from the St. Joseph's Foundation and the American Lung Association.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Likely Genetic Source Of Muscle Weakness Found
Simple genetic test by TGen reveals likely causes of disease, after other extensive testing failed; one child’s case produces discovery.
Monday, April 13, 2015
TGen-Led Study Identifies Genes Associated with Unhealthy Liver Function
Study with Geisinger Health System tests nearly 2,300 extremely obese diabetes patients.
Friday, October 04, 2013
TGen Seek Pancreatic-Cancer Patients for Trial
The Translational Genomics Research Institute is seeking 34 pancreatic-cancer patients at four sites around the country to participate in clinical trials that officials hope will bring them closer to a cure.
Thursday, December 01, 2011
Informatics Student Implements Real World Cancer Research
Alexis Christoforides, a first year Ph.D. candidate at Arizona State University’s Department of Biomedical Informatics, and full-time employee at the Translational Genomics Institute (TGen), renders class work to real world application.
Tuesday, November 29, 2011
TGen and Genomic Health Inc. Discover Genes Affecting Cancer Drug
A laboratory study indicates the need for more clinical research into the mechanisms that influence the activity of oxaliplatin.
Thursday, January 13, 2011
TGen Finds Therapeutic Targets for Rare Cancer in Children
RNAi screening used for the first time to study Ewing’s sarcoma.
Monday, September 06, 2010
First Arizona ‘Strides for Life’ Event Nets $25,000 for TGen Research
Lung Cancer Research Foundation already planning follow-up for 2011.
Tuesday, June 01, 2010
TGen Drug Development Partners with Horizon Discovery to offer an Integrated Personalized Medicine Service
Alliance will create a beginning-to-end solution to more rationally design and tailor their drugs to specific patient populations.
Monday, April 12, 2010
TGen Analysis Identifies Biomarkers for Diabetic Kidney Failure
Pooled DNA technique identifies variances that could indicate susceptibility to end-stage renal disease.
Monday, January 11, 2010
Forensics Firm Builds on Genomic Discovery to Advance DNA-based Identification
Casework Genetics is applying new technology to forensic evidence enabling law enforcement labs to solve crimes.
Thursday, October 29, 2009
Forensics Firm Builds on Genomic Discovery to Advance DNA-based Identification
New technology overcomes problem of mixed sample complexity
Wednesday, October 14, 2009
TGen Researchers Find Genetic Markers to Help Fight Diabetes
Scientists have identified five genetic biomarkers that could help lead to improved treatments for patients with diabetes.
Thursday, June 18, 2009
Cancer Research Helps Minimize Toxic Effects of Chemotherapy
Study shows how new screening tools help doctors decide which chemotherapy treatment to give patients based on their genetic makeup.
Monday, April 20, 2009
Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Searching Big Data Faster
Theoretical analysis could expand applications of accelerated searching in biology, other fields.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!